ABL Bio Secures $55 Million in R&D Funding to Accelerate Grabody Platform Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: PRnewswire
- Funding Support: ABL Bio has secured $55 million in R&D funding, including a $40 million upfront payment and a $15 million equity investment, which will significantly accelerate the development of its Grabody platform, particularly in expanding indications for high unmet need areas such as obesity and muscle disorders.
- Deepening Collaboration: In partnership with Eli Lilly, ABL Bio is conducting joint research on multiple therapeutic candidates, planning to leverage the newly secured funding to enhance collaboration and advance the development of bispecific antibodies and dual payload ADCs.
- Clinical Development Advancement: ABL Bio is advancing several clinical projects across eight pipelines in the U.S., China, Australia, and Korea, with ABL001 (tovecimig) receiving Fast Track designation from the FDA, indicating strong market potential.
- Long-term Strategy: By signing a $2.602 billion agreement with Lilly, ABL Bio not only secures immediate funding but also explores extensive collaborative opportunities for future therapy development, thereby enhancing its competitive position in the market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
